{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:04:19Z","timestamp":1793664259922,"version":"4.5.1"},"reference-count":79,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objective: Urinary tract infections (UTIs) are common in human medicine, affecting large patient populations worldwide. The principal cause of UTIs is uropathogenic Escherichia coli (UPEC) and Klebsiella, both in community and nosocomial settings. The assessment of local data on prevalence and resistance is essential to evaluate trends over time and to reflect on the national situation, compared to international data, using the methods of analytical epidemiology. Materials and Methods: The aim of this study was to assess resistance trends and epidemiology of UTIs caused by E. coli and Klebsiella species in inpatients and outpatients at a tertiary-care hospital in Hungary, using microbiological data. To evaluate resistance trends, several antibiotics were chosen as indicator drugs, based on local utilization data. Results: E. coli was the most prevalent isolate, representing 56.75 \u00b1 4.86% for outpatients and 42.29 \u00b1 2.94% for inpatients. For E. coli, the ratio of resistant strains for several antibiotics was significantly higher in the inpatient group, while in Klebsiella, similar trends were only observed for gentamicin. Extended-spectrum \u03b2-lactamase (ESBL)-producing isolates were detected in 4.33\u20139.15% and 23.22\u201334.22% from outpatient, 8.85\u201338.97% and 10.89\u201336.06% from inpatient samples for E. coli and Klebsiella, respectively. Conclusions: Resistance developments in common UTI pathogens (especially to fosfomycin, sulfamethoxazole-trimethoprim, fluoroquinolones, and 3rd generation cephalosporins), seriously curb therapeutic options, especially in outpatient settings.<\/jats:p>","DOI":"10.3390\/medicina55070356","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T03:05:26Z","timestamp":1562727926000},"page":"356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Comparative Epidemiology and Resistance Trends of Common Urinary Pathogens in a Tertiary-Care Hospital: A 10-Year Surveillance Study"],"prefix":"10.3390","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1270-0365","authenticated-orcid":false,"given":"M\u00e1ri\u00f3","family":"Gajd\u00e1cs","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, E\u00f6tv\u00f6s utca 6., 6720 Szeged, Hungary"},{"name":"Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged, Semmelweis utca 6., 6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"\u00c1br\u00f3k","sequence":"additional","affiliation":[{"name":"Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged, Semmelweis utca 6., 6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"L\u00e1z\u00e1r","sequence":"additional","affiliation":[{"name":"Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged, Semmelweis utca 6., 6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Buri\u00e1n","sequence":"additional","affiliation":[{"name":"Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged, Semmelweis utca 6., 6725 Szeged, Hungary"},{"name":"Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, D\u00f3m t\u00e9r 10., 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: Epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Walker","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","unstructured":"Bennett, J.E., Dolin, R., and Blaser, M.J. (2015). 74\u2014Urinary Tract Infections. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier. [8th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/antibiotics3030341","article-title":"Uncomplicated urinary tract infections and antibiotic resistance-epidemiological and mechanistic aspects","volume":"3","author":"Wiedemann","year":"2014","journal-title":"Antibiotics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10096-016-2673-1","article-title":"Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland","volume":"35","author":"Stefaniuk","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/antibiotics3020174","article-title":"Antimicrobial Stewardship and Urinary Tract Infections","volume":"3","author":"Abbo","year":"2014","journal-title":"Antibiotics (Basel)"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1099\/ijsem.0.001485","article-title":"Genome-based phylogeny and taxonomy of the \u201cEnterobacteriales\u201d: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov.","volume":"66","author":"Adeolu","year":"2016","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00431-016-2763-1","article-title":"Resistance to oral antibiotics in 4569 Gram-negative rods isolated from urinary tract infection in children","volume":"175","author":"Calzi","year":"2016","journal-title":"Eur. J. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5173\/ceju.2015.01.474","article-title":"Urinary tract infections and Candida albicans","volume":"68","author":"Behzadi","year":"2015","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1055\/a-0576-0079","article-title":"Escherichia coli and Klebsiella pneumoniae Sensitivity\/Resistance Pattern Towards Antimicrobial Agents in Primary and Simple Urinary Tract Infection Patients Visiting University Hospital of Jamia Hamdard New Delhi","volume":"68","author":"Rizwan","year":"2018","journal-title":"Drug Res. (Stuttg.)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijantimicag.2006.08.009","article-title":"Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections","volume":"28","author":"Kavaz","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.clinthera.2012.05.002","article-title":"Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort","volume":"34","author":"Alexander","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11845-012-0834-5","article-title":"An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999\u20132009","volume":"182","author":"Cullen","year":"2013","journal-title":"Ir. J. Med. Sci."},{"key":"ref_15","first-page":"111","article-title":"A survey on urinary tract infections associated with the three most common uropathogenic bacteria","volume":"5","author":"Behzadi","year":"2010","journal-title":"Maedica (Buchar)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1128\/JCM.02086-12","article-title":"Similarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection","volume":"50","author":"Luo","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fmicb.2017.01566","article-title":"UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies","volume":"8","author":"Terlizzi","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/jac\/dky499","article-title":"Klebsiella pneumoniae causing urinary tract infections in companion animals and humans: population structure, antimicrobial resistance and virulence genes","volume":"74","author":"Marques","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","first-page":"B4187","article-title":"Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli","volume":"58","year":"2011","journal-title":"Dan. Med. Bull."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.idc.2013.10.003","article-title":"Diagnosis and management of urinary tract infection in the emergency department and outpatient settings","volume":"28","author":"Takhar","year":"2014","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yexmp.2008.03.007","article-title":"Origins and Virulence Mechanisms of Uropathogenic Escherichia coli","volume":"85","author":"Wiles","year":"2008","journal-title":"Exp. Mol. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vading, M., Naucl\u00e9r, P., Kalin, M., and Giske, C.G. (2018). Invasive infection caused by Klebsiella pneumoniae is a disease affecting patients with high comorbidity and associated with high long-term mortality. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195258"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/cid\/cit675","article-title":"Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in China","volume":"58","author":"Li","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2018.1522249","article-title":"Multidrug-resistant klebsiella pneumoniae: Challenges for treatment, prevention and infection control","volume":"16","author":"Bassetti","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/00325481.2017.1246055","article-title":"An update on the management of urinary tract infections in the era of antimicrobial resistance","volume":"129","author":"Bader","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0891-5520(03)00004-7","article-title":"The current management strategies for community-acquired urinary tract infection","volume":"17","author":"Hooton","year":"2003","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0463.2009.02563.x","article-title":"Beta-lactam Antibiotics: From Antibiosis to Resistance and Bacteriology","volume":"118","author":"Kong","year":"2010","journal-title":"APMIS"},{"key":"ref_28","first-page":"625170","article-title":"ESBLs: A Clear and Present Danger?","volume":"2012","author":"Dhillon","year":"2012","journal-title":"Crit. Care Res. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003495-200363040-00002","article-title":"Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment","volume":"63","author":"Rupp","year":"2003","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: A clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jac\/dkg284","article-title":"AmpC \u03b2-lactamases: what do we need to know for the future?","volume":"52","author":"Hanson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e01076-18","DOI":"10.1128\/AAC.01076-18","article-title":"Past and Present Perspectives on \u03b2-Lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1469-0691.2011.03703.x","article-title":"EUCAST expert rules in antimicrobial susceptibility testing","volume":"19","author":"Leclercq","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","first-page":"24","article-title":"Prevalence of Types TEM, SHV and CTX-M \u03b2LES Among Pathogens of Chronic Pyelonephritis","volume":"59","author":"Bilchenko","year":"2014","journal-title":"Antibiot. Khimioter."},{"key":"ref_36","first-page":"110","article-title":"CTX-M Enzymes: Origin and Diffusion","volume":"3","year":"2012","journal-title":"Front. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.juro.2011.02.1190","article-title":"Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase (ESBL) producing pathogens at a tertiary care swiss University Hospital","volume":"185","author":"Bonkat","year":"2011","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3747521","DOI":"10.1155\/2018\/3747521","article-title":"Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems","volume":"2018","author":"Walker","year":"2018","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/cid\/ciw396","article-title":"Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens","volume":"63","author":"Walker","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1684-1182(10)60038-2","article-title":"Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum \u03b2-lactamase (ESBL) and non-ESBL producing Escherichia coli","volume":"43","author":"Hsieh","year":"2010","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"iii25","DOI":"10.1093\/jac\/dkq298","article-title":"Complicated urinary tract infections: Practical solutions for the treatment of multiresistant gram-negative bacteria","volume":"65","author":"Pallett","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/14787210.2018.1453807","article-title":"Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam\u2014Epidemiology, laboratory detection and treatment implications","volume":"16","author":"Sherry","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1155\/2013\/645018","article-title":"Determination of susceptibility to fosfomycin and tigecycline of Enterobacteriaceae, particularly Escherichia coli isolates, producing extended-spectrum \u03b2-lactamases from multiple regional Canadian hospitals","volume":"24","author":"Beuk","year":"2013","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_44","first-page":"31","article-title":"Extra deaths due to pandrug resistant bacteria: A survey of the literature","volume":"60","year":"2019","journal-title":"Eg\u00e9szs\u00e9gfejleszt\u00e9s"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"f1585","DOI":"10.1136\/bmj.f1585","article-title":"Outpatient parenteral antimicrobial therapy","volume":"346","author":"Chapman","year":"2013","journal-title":"BMJ"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10096-012-1668-9","article-title":"Antibiotic prescription by general practitioners for urinary tract infections in outpatients","volume":"31","author":"Denes","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"i939","DOI":"10.1136\/bmj.i939","article-title":"Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis","volume":"352","author":"Bryce","year":"2016","journal-title":"BMJ"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fasugba, O., Mitchell, B.G., Mnatzaganian, G., Das, A., Collignon, P., and Gardner, A. (2016). Five-Year Antimicrobial Resistance Patterns of Urinary Escherichia coli at an Australian Tertiary Hospital: Time Series Analyses of Prevalence Data. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164306"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1099\/jmm.0.000498","article-title":"Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary","volume":"66","author":"Magyar","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/1120009X.2017.1418646","article-title":"Analysis of the spectrum and antibiotic resistance of uropathogens in outpatients a tertiary hospital","volume":"30","author":"Yang","year":"2018","journal-title":"J. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009\u20132012","volume":"43","author":"Sader","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_53","first-page":"249","article-title":"The opinions of community pharmacists related to antibiotic use and resistance","volume":"88","author":"Paulik","year":"2018","journal-title":"Acta Pharmaceutica Hungarica"},{"key":"ref_54","first-page":"26","article-title":"The attitude of community pharmacists towards their widening roles in the prevention and treatment of infectious diseases in the southeast region of Hungary","volume":"63","author":"Paulik","year":"2019","journal-title":"Gy\u00f3gyszer\u00e9szet"},{"key":"ref_55","unstructured":"National Health Insurance Fund of Hungary (2017). Hospital Bed Count and Patient Turnover Report 2017, National Health Insurance Fund of Hungary."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M., Spengler, G., and Urb\u00e1n, E. (2017). Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik\u2019s Cube of Clinical Microbiology?. Antibiotics (Basel), 6.","DOI":"10.3390\/antibiotics6040025"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.mimet.2017.11.021","article-title":"Combination of MALDI-TOF MS and PBP2\u2019 latex agglutination assay for rapid MRSA detection","volume":"144","year":"2018","journal-title":"J. Microbiol. Methods"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1099\/jmm.0.043927-0","article-title":"The value of MALDI-TOF MS for the identification of clinically relevant anaerobic bacteria in routine laboratories","volume":"61","author":"Nagy","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"ref_59","first-page":"1839","article-title":"Antibiotic use in the Hungarian hospitals in the last two decades (1996\u20132015)","volume":"157","author":"Matuz","year":"2016","journal-title":"Orv. Hetil."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1556\/OH.2013.29632","article-title":"Evaluation of ambulatory antibiotic use in Hungary using drug-specific quality indicators","volume":"154","author":"Matuz","year":"2013","journal-title":"Orv. Hetil."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1469-0691.2007.01852.x","article-title":"Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline","volume":"14","author":"Garau","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000339200","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: In vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline","volume":"21","author":"Senok","year":"2012","journal-title":"Med. Princ. Pract."},{"key":"ref_63","unstructured":"(2019, May 28). European Antimicrobial Resistance Surveillance Network (EARS-Net). Available online: https:\/\/ecdc.europa.eu\/en\/about-us\/partnerships-and-networks\/disease-and-laboratory-networks\/ears-net."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2005.08.016","article-title":"Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991\u20132003 at a university hospital in Taiwan","volume":"26","author":"Hsueh","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Spengler, G., Kincses, A., Gajdacs, M., and Amaral, L. (2017). New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria. Molecules, 22.","DOI":"10.3390\/molecules22030468"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.mayocp.2011.12.003","article-title":"Mechanisms of Resistance and Clinical Relevance of Resistance to \u03b2-Lactams, Glycopeptides, and Fluoroquinolones","volume":"87","author":"Rice","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1556\/030.62.2015.3.2","article-title":"Identification and characterization of CTX-M-15 producing Klebsiella pneumoniae clone ST101 in a Hungarian university teaching hospital","volume":"62","author":"Melegh","year":"2015","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QCO.0000000000000228","article-title":"Global epidemiology of urinary tract infections","volume":"29","author":"Tandogdu","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_69","first-page":"460","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"Doi","year":"2016","journal-title":"Virulence"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Codjoe, F.S., and Donkor, E.S. (2017). Carbapenem Resistance: A Review. Med. Sci. (Basel), 6.","DOI":"10.3390\/medsci6010001"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2125.2005.02525.x","article-title":"Regional variations in community consumption of antibiotics in Hungary, 1996\u20132003","volume":"61","author":"Matuz","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_73","unstructured":"(2019, May 28). European Surveillance of Antimicrobial Consumption Network (ESAC-Net). Available online: http:\/\/ecdc.europa.eu\/en\/about-us\/partnerships-and-networks\/disease-and-laboratory-networks\/esac-net."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M. (2019). The Concept of an Ideal Antibiotic: Implications for Drug Design. Molecules, 24.","DOI":"10.3390\/molecules24050892"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: Design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_76","unstructured":"World Health Organisation (2017). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics, WHO."},{"key":"ref_77","first-page":"209","article-title":"Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: Results from a 10-year retrospective survey","volume":"72","year":"2019","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_78","unstructured":"Gajd\u00e1cs, M., \u00c1br\u00f3k, M., L\u00e1z\u00e1r, A., and Buri\u00e1n, K. (2019). Susceptibility patterns of extended-spectrum beta-lactamase-producing (ESBL) urinary pathogens: single-center experience. Gy\u00f3gyszer\u00e9szet, accepted. (In Hungarian)."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M., and Urb\u00e1n, E. (2019). Resistance Trends and Epidemiology of Citrobacter-Enterobacter-Serratia in Urinary Tract Infections of Inpatients and Outpatients (RECESUTI): A 10-Year Survey. Medicina (Kaunas), 55.","DOI":"10.3390\/medicina55060285"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/7\/356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:03:58Z","timestamp":1760187838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/7\/356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["medicina55070356"],"URL":"https:\/\/doi.org\/10.3390\/medicina55070356","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,9]]}}}